Photo by nci from unsplash
In the REWIND CV outcomes trial, the addition of dulaglutide 1.5 mg (DU) vs placebo (PL) to standard of care reduced the composite risk of CV death, nonfatal MI and… Click to show full abstract
In the REWIND CV outcomes trial, the addition of dulaglutide 1.5 mg (DU) vs placebo (PL) to standard of care reduced the composite risk of CV death, nonfatal MI and nonfatal stroke in patients with type 2 diabetes and prior CV disease or CV risk factors. DU also reduced glycated hemoglobin (HbA1c)
Keywords:
antihyperglycemic agents;
trial;
reduces hba1c;
irrespective antihyperglycemic;
dulaglutide reduces;
hba1c irrespective
Journal Title: Journal of the American College of Cardiology
Year Published: 2020
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!
Journal Title: Journal of the American College of Cardiology
Year Published: 2020
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!